

Overuse of thrombopoietin receptor agonists driven by suboptimal response is associated with myelofibrosis in pediatric immune thrombocytopenia

Authors

Jingyao Ma,¹ Zhenping Chen,² Xiaoling Cheng,³ Yu Hu,¹ Jin Jiang,¹ Jie Ma,¹ Hongyun Lian,¹ Liqiang Zhang,¹ Xinyue Ma,¹ Xi Lin,¹ Shuyue Dong,¹ Chuo Li,¹ Wanru Yao,¹ Shasha Zhao,¹ Yunyun Wei¹ and Runhui Wu¹

¹Hematology Department; ²Cell and Gene Therapy Laboratory, Beijing Pediatric Research Institute and ³Pharmacology Center; Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China

Correspondence:

R. WU - runhuiwu@hotmail.com

Z. CHEN - chenzhenping@outlook.com

<https://doi.org/10.3324/haematol.2026.300651>

Received: January 31, 2026.

Accepted: April 3, 2026.

Early view: May 7, 2026.

©2026 Ferrata Storti Foundation

Published under a CC BY-NC license 

Supplementary Materials

Overuse of thrombopoietin receptor agonists driven by suboptimal response is associated with myelofibrosis in pediatric immune thrombocytopenia

Table S1. Complete Blood Count and Peripheral Blood Smear Findings at the Time of Bone Marrow Biopsy

Characteristics	Total (n=54)	MF 0-1 (n=40)	MF ≥ 2 (n=14)	P-value
Platelet count, ×10 ⁹ /L, median (IQR)	55.0 (15.0-112.0)	51.0 (15.0-92.5)	76.0 (16.2-125.8)	0.621
White blood cell count, ×10 ⁹ /L, median (IQR)	9.8 (6.8-11.1)	9.2 (7.0-11.3)	10.1 (7.3-11.1)	0.701
Neutrophil count, ×10 ⁹ /L, median (IQR)	6.6 (3.8-8.3)	5.5 (3.7-8.0)	7.3 (5.2-10.2)	0.246
Hemoglobin, g/L, median (IQR)	119.0 (106.0-130.0)	121.0 (109.5-130.0)	112.5 (104.5-126.5)	0.167
Teardrop cells on peripheral smear, n (%)	0 (0.0)	0 (0.0)	0 (0.0)	1.000

Abbreviations: MF, myelofibrosis; IQR, interquartile range.

Continuous variables are presented as median (IQR) and compared using the Mann-Whitney U test. Categorical variables are presented as count (percentage) and compared using Fisher's exact test.

Table S2. Distribution of Specific TPO-RA Agents Used Prior to Bone Marrow Biopsy

TPO-RA Agent Exposure	Total (n=54)	MF 0-1 (n=40)	MF ≥ 2 (n=14)	P-value
Eltrombopag, n (%)	38 (70.4)	29 (72.5)	9 (64.3)	0.735
Avatrombopag, n (%)	35 (64.8)	21 (52.5)	14 (100.0)	0.001
Hetrombopag, n (%)	13 (24.1)	7 (17.5)	6 (42.9)	0.075
Romiplostim, n (%)	5 (9.3)	2 (5.0)	3 (21.4)	0.103
Multiple TPO-RAs used, n (%)	28 (51.9)	16 (40.0)	12 (85.7)	0.005

Abbreviations: MF, myelofibrosis; TPO-RA, thrombopoietin receptor agonist.

Categorical variables are presented as count (percentage) and compared using Fisher's exact test. Note that patients could have been exposed to more than one TPO-RA agent due to switching, hence the percentages do not sum to 100%.